We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer (ICEBERG 2)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00494442
First Posted: June 29, 2007
Last Update Posted: October 16, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
KuDOS Pharmaceuticals Limited
Information provided by (Responsible Party):
AstraZeneca
  Purpose
The purpose of the study is to see if the drug KU 0059436 is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and for whom no curative therapeutic option exists.

Condition Intervention Phase
Ovarian Neoplasm Drug: KU-0059436 (AZD2281)(PARP inhibitor) Phase 2

An investigational treatment associated with this study has been approved for sale to the public.   More info ...

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Ovarian Cancer

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Confirmed Objective Tumour Response (According to Response Evaluation Criteria In Solid Tumors (RECIST) [ Time Frame: Baseline, every 8 also at study termination or initiation of confounding anti-cancer therapy. ]
    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease from baseline in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.


Secondary Outcome Measures:
  • Clinical Benefit (CB) [ Time Frame: End of study ]
    Clinical Benefit (CB) is defined as the percentage of patients with a RECIST tumour response of confirmed complete response, partial response or stable disease for ≥8 weeks)

  • Duration of Response [ Time Frame: End of study ]
    Duration of response to olaparib

  • Best Percentage Change in Tumour Size [ Time Frame: End of study ]
    The best % change (reduction) from baseline in tumour size (defined as the sum of the longest diameters as measured among all target lesions).

  • Progression-Free Survival (PFS) [ Time Frame: End of study ]
    Progression-Free Survival (PFS) is defined as the time from first dose to the earlier date of radiologic progression (as per RECIST criteria) or death by any cause in the absence of objective progression.


Enrollment: 57
Actual Study Start Date: June 11, 2007
Study Completion Date: July 20, 2017
Primary Completion Date: March 17, 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: KU-0059436 (AZD2281) 100 mg BID Drug: KU-0059436 (AZD2281)(PARP inhibitor)
oral
Other Name: Olaparib
Experimental: KU-0059436 (AZD2281) 400 mg BID Drug: KU-0059436 (AZD2281)(PARP inhibitor)
oral

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 130 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Advanced ovarian cancer with positive BRCA1 or BRCA2 status
  • Failed at least one prior chemotherapy
  • In investigators opinion, no curative standard therapy exists
  • Measurable disease

Exclusion Criteria:

  • Brain metastases
  • Less than 28 days since last treatment used to treat the disease
  • Considered a poor medical risk due to a serious uncontrolled disorder
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00494442


Locations
United States, California
Research Site
Los Angeles, California, United States, 90048
Research Site
San Francisco, California, United States, 94115
United States, Massachusetts
Research Site
Boston, Massachusetts, United States, 02115
United States, New York
Research Site
New York, New York, United States, 10065
United States, Texas
Research Site
Houston, Texas, United States, 77030
Australia
Research Site
Melbourne, Parkville, Australia, VIC 3050
Research Site
Melbourne, Australia, 3000
Research Site
Randwick, Australia, 2031
Germany
Research Site
Köln, Germany, 50931
Spain
Research Site
Hospitalet deLlobregat, Spain, 08907
Sweden
Research Site
Lund, Sweden, S-221 85
Sponsors and Collaborators
AstraZeneca
KuDOS Pharmaceuticals Limited
Investigators
Study Director: James Carmichael, BSc MBChB MD FRCP KuDOS Pharmaceuticals Limited
Principal Investigator: Andrew Tutt, PhD MRCP FRCR Guy's and St Thomas's NHS Foundation Trust, London, UK
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00494442     History of Changes
Other Study ID Numbers: KU36-58
D0810C00009
First Submitted: June 27, 2007
First Posted: June 29, 2007
Results First Submitted: January 15, 2015
Results First Posted: January 26, 2015
Last Update Posted: October 16, 2017
Last Verified: September 2017

Keywords provided by AstraZeneca:
Advanced ovarian cancer
Poly(ADP ribose) polymerases
KU-0059436
AZD2281
BRCA1 protein
BRCA2 protein

Additional relevant MeSH terms:
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Poly(ADP-ribose) Polymerase Inhibitors
Olaparib
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents